Back to Blogs
Blog Img

Australia is an attractive place to conduct MedTech clinical research

”Australia is an attractive place to conduct MedTech clinical research. This was the key topic at this morning’s MTPConnect session at the international MedTech conference. Key points:

Australia has a sophisticated medical research environment; there’s a streamlined clinical trials notification scheme with rapid approvals and a robust regulatory framework; the data collected is transferable and recognised by other regulatory authorities.

Australia is 28% cheaper than the US and 60% cheaper after tax incentives, for early phase clinical trials.

Australia has an ethnically diverse multi-lingual population; Western disease patterns; is close to Asian markets backed by Free Trade Agreements and has globally recognised KOLs in major therapeutic areas.

Australia has world-class clinical trials infrastructure with high quality facilities including for early phase device and preclinical studies; and established expertise in conducting device based trials.

Thank you to the speakers:
Peter McGauran
Daniel Grant
Jason Kovacic
Gemma Figtree
Falko Thiele

Presented by MTPConnect, Austrade and the Australian Cardiovascular Alliance.

HPG (Healthcare Professionals Group)